Table 2.
Essential items that should be described in observational studies, according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) declaration.
Items | Roy et al. (2007 | Ryu et al. (2015) |
---|---|---|
Title and abstract | ||
1.1 Indicate the study's design with a commonly used term in the title or the abstract | + | + |
1.2 Provide in the abstract an informative and balanced summary of what was done and what was found | + | + |
Introduction | ||
2. Explain the scientific background and rationale for the investigation being reported | + | + |
3. State specific objectives, including any prespecified hypotheses. | + | + |
Methods | ||
4. Present key elements of study design early in the paper. | − | + |
5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | + | + |
6.1 Give the eligibility criteria, and the sources and methods of selection of participants. | + | + |
7. Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | ? | ? |
8. For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | ? | + |
9. Describe any efforts to address potential sources of bias | − | − |
10. Explain how the study size was arrived at | ? | − |
11. Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | ? | ? |
12.1 Describe all statistical methods, including those used to control for confounding. | + | + |
12.2 Describe any methods used to examine subgroups and interactions | + | − |
12.3 Explain how missing data were addressed(“missing data”) | − | − |
12.4 If applicable, describe analytical methods taking account of sampling strategy. | − | + |
12.5 Describe any sensitivity analyses. | − | − |
Results | ||
13.1 Report numbers of individuals at each stage of study; e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | ? | − |
13.2 Give reasons for non-participation at each stage. | − | − |
13.3 Consider use of a flow diagram | − | − |
14.1 Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders. | + | + |
14.2 Indicate number of participants with missing data for each variable of interest. | − | − |
15. Report numbers of outcome events or summary measures. | + | + |
16.1 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% Confidence Interval). Make clear which confounders were adjusted for and why they were included. | − | − |
16.2 Report category boundaries when continuous variables were categorized. | + | + |
16.3 If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. | − | − |
17. Report other analyses done (e.g. analyses of subgroups and interactions), and sensitivity analyses. | + | − |
Discussion | ||
18. Summarize key results with reference to study objectives. | + | + |
19. Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | − | + |
20. Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. | + | + |
21. Discuss the generalizability (external validity) of the study results. | + | + |
Other information | ||
22. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based. | − | + |